Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA,
Department of Surgery, Surgical Health Outcomes and Research Enterprise, University of Rochester Medical Center, Rochester, New York, USA.
Dig Surg. 2020;37(2):163-170. doi: 10.1159/000498865. Epub 2019 Mar 5.
BACKGROUND/AIMS: Transfusion rates in colon cancer surgery are traditionally very high. Allogeneic red blood cell (RBC) transfusions are reported to induce immunomodulation that contributes to infectious morbidity and adverse oncologic outcomes. In an effort to attenuate these effects, the study institution implemented a universal leukocyte reduction protocol. The purpose of this study was to examine the impact of leukocyte-reduced (LR) transfusions on postoperative infectious complications, recurrence-free survival, and overall survival (OS).
In a retrospective study, patients with stage I-III adenocarcinoma of the colon from 2003 to 2010 who underwent elective resection were studied. The primary outcome measures were postoperative infectious complications and recurrence-free and OS in patients that received a transfusion. Bivariate and multivariable regression analyses were performed for each endpoint.
Of 294 patients, 66 (22%) received a LR RBC transfusion. After adjustment, transfusion of LR RBCs was found to be independently associated with increased infectious complications (OR 3.10, 95% CI 1.24-7.73), increased odds of cancer recurrence (hazard ratio [HR] 3.74, 95% CI 1.94-7.21), and reduced OS when ≥3 units were administered (HR 2.24, 95% CI 1.12-4.48).
Transfusion of LR RBCs is associated with an increased risk of infectious complications and worsened survival after elective surgery for colon cancer, irrespective of leukocyte reduction.
背景/目的:传统上,结肠癌手术中的输血率非常高。据报道,异体红细胞(RBC)输血可诱导免疫调节,从而导致感染发病率和不良的肿瘤学结局。为了减轻这些影响,研究机构实施了通用白细胞减少协议。本研究的目的是检查白细胞减少(LR)输血对术后感染并发症、无复发生存和总生存(OS)的影响。
在一项回顾性研究中,研究了 2003 年至 2010 年间接受择期切除术的 I-III 期结肠癌腺癌患者。主要观察指标是接受输血的患者的术后感染并发症、无复发生存和 OS。对每个终点进行了双变量和多变量回归分析。
在 294 名患者中,66 名(22%)接受了 LR RBC 输血。调整后,LR RBC 输血与感染并发症增加(OR 3.10,95%CI 1.24-7.73)、癌症复发风险增加(HR 3.74,95%CI 1.94-7.21)独立相关,并且当给予≥3 个单位时,OS 降低(HR 2.24,95%CI 1.12-4.48)。
无论白细胞减少与否,LR RBC 输血与择期结肠癌手术后感染并发症风险增加和生存恶化相关。